1-(3-硝基吡啶-2-基)哌嗪 | 87394-48-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(3-硝基吡啶-2-基)哌嗪
• 中文别名: 1-(3-硝基-2-吡啶基)哌嗪
• 英文名称: 1-(3-nitro-2-pyridinyl)piperazine
• 英文别名: 1-(3-nitro-2-pyridyl)piperazine；1-(3-nitro-pyridin-2-yl)piperazine；1-(3-Nitropyridin-2-yl)piperazine
• CAS: 87394-48-7
• 化学式: C₉H₁₂N₄O₂
• mdl: MFCD05182227
• 分子量: 208.22
• InChiKey: HSAKGWZDXDRYTB-UHFFFAOYSA-N

物化性质

• 熔点：
  84-86
• 沸点：
  387.8±37.0 °C(Predicted)
• 密度：
  1.278±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  74
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
1-(3-Nitropyridin-2-yl)piperazine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
1-(3-Nitropyridin-2-yl)piperazine
Ingredient name:
CAS number: 87394-48-7

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H12N4O2
Molecular weight: 208.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(3-硝基吡啶-2-基)哌嗪 在 palladium on activated charcoal 氢气 、 sodium cyanoborohydride 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 1-((1,1-二甲基乙氧基)羰基)-4-(3-((1-甲基乙基)氨基)-2-吡啶)哌嗪
  参考文献：
  名称：

  带有芳基吡咯部分的新delavirdine类似物的合成和抗HIV-1活性。

  摘要：

  在我们寻找新型抗人免疫缺陷病毒（HIV）-1药物的过程中，合成了14种地拉维定类似物，并在基于细胞的测定中评估为潜在的抗HIV-1药物。化合物1Aa在急性感染的MT4细胞中表现出有效的和选择性的抗HIV-1活性，其有效浓度（EC50）值在亚微摩尔范围内。

  DOI：

  10.1248/cpb.49.1406
• 作为产物：
  描述：

  哌嗪 生成 1-(3-硝基吡啶-2-基)哌嗪
  参考文献：
  名称：

  NEW, JAMES S.;LOBECK, WALTER G.;YEVICH, JOSEPH P.

  摘要：

  DOI：

文献信息

• [EN] PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRIMIDO[5,4-D]PYRIMIDINE SERVANT D'INHIBITEURS D'ENT POUR LE TRAITEMENT DE CANCERS, ET LEUR COMBINAISON AVEC DES ANTAGONISTES DU RÉCEPTEUR DE L'ADÉNOSINE
  申请人：ITEOS BELGIUM SA

  公开号：WO2021170797A1

  公开（公告）日：2021-09-02

  The present invention relates to pyrimido[5,4-d]pyrimidine derivatives of formula (I), including pharmaceutically acceptable salts and solvates thereof. Compounds of the invention are inhibitors of ENT family transporter, especially of ENT1, and are useful as therapeutic compounds for the treatment of cancers. The invention also relates to the combined use of the pyrimido[5,4-d]pyrimidine derivatives with an adenosine receptor antagonist, for the treatment of cancers.

  本发明涉及式(I)的嘧啶并[5,4-d]嘧啶衍生物，包括其药用可接受盐和溶剂化合物。本发明的化合物是ENT家族转运蛋白的抑制剂，特别是ENT1的抑制剂，并且可用作治疗癌症的治疗化合物。该发明还涉及将嘧啶并[5,4-d]嘧啶衍生物与腺苷受体拮抗剂联合使用，用于治疗癌症。
• Acetamides and benzamides that are useful in treating sexual dysfunction
  申请人：——

  公开号：US20040029887A1

  公开（公告）日：2004-02-12

  The present invention relates to the use of compounds of formula (I) 1 for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

  本发明涉及使用式(I)的化合物治疗性功能障碍，以及含有式(I)化合物的组合物用于治疗性功能障碍。
• REMEDIES OR PREVENTIVES FOR AIDS
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0878194A1

  公开（公告）日：1998-11-18

  The present invention is to provide the combined use of one kind or two or more kinds of a quinolone carboxylic acid having anti-HIV activity and one kind or two or more kinds of a reverse transcriptase inhibitor or HIV protease inhibitor, and an AIDS therapeutic agent or preventive agent containing as its active ingredients one kind or two or more kinds of a quinolone carboxylic acid having anti-HIV activity and one kind or two or more kinds of a reverse transcriptase inhibitor or HIV protease inhibitor.

  本发明提供了一种或两种或两种以上具有抗HIV活性的喹诺酮羧酸与一种或两种或两种以上的逆转录酶抑制剂或HIV蛋白酶抑制剂的联合使用，以及一种包含作为其活性成分的抗HIV活性的喹诺酮羧酸和一种或两种或两种以上的逆转录酶抑制剂或HIV蛋白酶抑制剂的艾滋病治疗剂或预防剂。
• Substituted piperazines as metabotropic glutamate receptor antagonists
  申请人：Edwards Louise

  公开号：US20070037820A1

  公开（公告）日：2007-02-15

  The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar 1 , Ar 2 , Hy, L, R 1 , m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses thereof, processes for making the compounds, as well as methods for the medical treatment of mGluR5-mediated disorders.

  这项发明涉及公式I的化合物或其药用可接受的盐或溶剂： 其中Ar1，Ar2，Hy，L，R1，m和n如描述中所定义。该发明还包括药物组合物及其用途，制备这些化合物的方法，以及治疗mGluR5介导的疾病的方法。
• [EN] TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS<br/>[FR] COMPOSES DE TETRAZOLE ET LEUR UTILISATION COMME ANTAGONISTES DE RECEPTEURS DE GLUTAMATE METABOTROPIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2005080356A1

  公开（公告）日：2005-09-01

  The present invention relates to new compounds of formula I, wherein P, Q, X1, X2, X3, X4, R1, R2, m and p, are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds, and to the use of said compounds in therapy.

  本发明涉及公式I的新化合物，其中P、Q、X1、X2、X3、X4、R1、R2、m和p如公式I中所定义，或其盐、溶剂合物或溶剂化盐，其制备方法及用于制备所述化合物的新中间体，含有所述化合物的药物组合物，以及所述化合物在治疗中的使用。